Affiliation:
1. Office of the Chief Medical Examiner, 4312 District Dr, Raleigh, NC 27607, USA
2. UNC Department of Pathology and Laboratory Medicine, 160 Medical Dr., Chapel Hill, NC 27559, USA
Abstract
Abstract
Buprenorphine (BUP) is a commonly prescribed medication for the treatment of opioid use disorder (OUD). As prescriptions increase in North Carolina, BUP is more frequently encountered statewide in routine postmortem casework. Between 2010 and 2018, there were 131 select cases investigated by the Office of the Chief Medical Examiner where BUP was detected in peripheral blood and considered a primary cause of death (COD), with no other opioids present and no other non-opioid substances found in the lethal range. The decedents ranged in age from 14 to 64 years, with 67% male. The mean/median peripheral blood concentrations were 4.1/2.1 ng/mL for BUP and 7.8/3.4 ng/mL for its metabolite, norbuprenorphine. These postmortem blood concentrations overlap antemortem therapeutic concentrations in plasma reported in the literature for opioid-dependent subjects receiving sublingual maintenance therapy. The pathologist considered scene findings, prescription history, autopsy findings, toxicological analysis and decedent behavior prior to death to conclude a drug-related COD. Many of the deaths were complicated by the presence of other central nervous system depressants along with contributory underlying cardiovascular and respiratory disease. The three most prevalent additive substances were alprazolam, ethanol and gabapentin, found in 67, 36 and 32 cases out of 131, respectively. Interpreting BUP involvement in a death is complex, and instances may be underestimated in epidemiological data because of the lack of a defined toxic or lethal range in postmortem blood along with its good safety profile. As expansion of access to OUD treatment becomes a priority, awareness of the challenges of postmortem interpretation is needed as increased use and diversion of BUP are inevitable.
Publisher
Oxford University Press (OUP)
Subject
Chemical Health and Safety,Health, Toxicology and Mutagenesis,Toxicology,Environmental Chemistry,Analytical Chemistry
Reference77 articles.
1. Medication-assisted treatment for opioid-use disorder;Oesterle;Mayo Clinic Proceedings,2019
2. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration;Buprenorphine,2021
3. Clinical pharmacology of buprenorphine: ceiling effects at high doses;Walsh;Clinical Pharmacology and Therapeutics,1994
4. Buprenorphine induces ceiling in respiratory depression but not in analgesia;Dahan;British Journal of Anaesthesia,2006
5. Effects of high-dose intravenous buprenorphine in experienced opioid abusers;Umbricht;Journal of Clinical Psychopharmacology,2004
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献